Clark Estates’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-113,918
Closed -$3.58M – 93
2026
Q2
$3.58M Hold
113,918
– – 0.83% 20
2026
Q1
$2.82M Hold
113,918
– – 0.68% 22
2025
Q4
$2.66M Hold
113,918
– – 0.65% 26
2025
Q3
$2.24M Hold
113,918
– – 0.51% 46
2025
Q2
$2.47M Sell
113,918
-20,500
-15% -$484K 0.55% 22
2025
Q1
$3.26M Sell
134,418
-51,325
-28% -$1.16M 0.69% 17
2024
Q4
$3.88M Sell
185,743
-22,507
-11% -$484K 0.75% 20
2024
Q3
$4.14M Sell
208,250
-16,700
-7% -$310K 0.77% 21
2024
Q2
$3.48M Sell
224,950
-6,050
-3% -$94.2K 0.65% 35
2024
Q1
$3.68M Buy
231,000
+33,500
+17% +$505K 0.61% 41
2023
Q4
$3.32M Buy
197,500
+9,500
+5% +$130K 0.56% 56
2023
Q3
$2.2M Buy
+188,000
New +$2.51M 0.4% 79

Other funds holding CPRX

Clark Estates's CPRX Position: Q3 2026 in Review

Clark Estates sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 113,918 shares — an estimated $3.58M sold.

Clark Estates first reported a position in CPRX in Q3 2023 and held it in 12 quarters. The position peaked at $4.14M in Q3 2024. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Clark Estates reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Clark Estates sold 113,918 Catalyst Pharmaceutical shares in Q3 2026, an estimated $3.58M.
  • Clark Estates first reported a position in Catalyst Pharmaceutical in Q3 2023 and held it in 12 quarters.
  • Clark Estates's Catalyst Pharmaceutical position peaked at $4.14M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Clark Estates's 13F filing for Q3 2026, filed 10 Nov 2026.